Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Ozurdex® (dexamethasone 0.7mg) now available for millions of patients in China with macular edema secondary to retinal vein occlusion

Allergan
Posted on: 23 Mar 18

--An estimated 7.4 million people in China are living with this sight-threatening condition[i],[ii],[iii] --

 

DUBLIN, IRELAND MARCH 17, 2018 Today, Allergan plc (NYSE:AGN) announces the launch of Ozurdex® (dexamethasone intravitreal implant 0.7 mg) in China for the treatment of adult patients with macular edema secondary to retinal vein occlusion (RVO). RVO is the second most common type of retinal vascular disorder after diabetic retinal disease[iv] and it is estimated that 7.4 million people in China are living with the condition.i,ii,iii

 

RVO is caused by blockages in the central retinal vein (CRVO) or in the surrounding branch retinal veins (BRVO) which leads to disrupted blood flow, haemorraghing and eventually macular edema.[v] If left untreated, RVO can result in sudden and painless loss of vision.[vi] Symptoms of the disease include blurry vision and floaters (dark spots and lines in vision).[vii], [viii]

 

Ozurdex® is the first approved intravitreal injection for RVO in China and is licensed for the treatment of macular edema following BRVO and CRVO. Allergan has accelerated access to this treatment in 27 hospitals across China, making it available as a first-line treatment for this potentially sight-threatening condition. Ozurdex® was put on the priority approval list by the Chinese Food and Drug Administration (CFDA) and was granted an Imported Drugs Licence (IDL) in October 2017.

 

Dr. Dai Hong, Director of Ophthalmology at Beijing Hospital comments, “RVO is a devastating condition that affects millions of patients in China. It can lead to macular edema, the thickening of the macular region in the eye, and if left untreated results in poor vision. Macular edema is the leading cause of visual impairment in RVO. Being able to offer these patients a proven treatment option allows ophthalmologists to consider a more tailored management approach, helping to reduce the treatment burden for patients and alleviate pressure on local eye care services.”

 

Ozurdex® is a biodegradable implant containing the anti-inflammatory corticosteroid, dexamethasone. It is implanted in the back of the eye, via a single use applicator, and the implant slowly releases dexamethasone directly to the retina over a period of several months.[ix] Inflammation plays a role in the development of RVO and is a critical component in macular edema.[x] This treatment works by suppressing inflammatory mediators and delivers sustained visual gains.[xi]

 

“Providing millions of RVO patients access to Ozurdex® is a significant step towards preventing blindness and meeting a critical unmet need in China,” comments Marc Princen, Allergan International President. “As the global prevalence of eye diseases grows, Allergan remains committed to reducing this burden and delivering innovative treatments to people most in need around the world.”

Editor's Details

Mike Wood
PharmiWeb.com
www.pharmiweb.com
editor@pharmiweb.com

Last updated on: 23/03/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.